Skip to main content
Arzon Global Icon

ARZON

BACK TO BLOG HUB
Pharmacovigilance 12 min read Published 2026-09-12

Pharmacovigilance Aggregate Safety Reporting & PBRER/PSUR Masterclass 2026

An advanced operational guide for Drug Safety Scientists breaking into PV Aggregate Reporting, Periodic Benefit-Risk Evaluation Reports (PBRER), and PSUR submissions.

AUTHOR: Kumail Raza & Arzon Safety Unit (Senior PV Aggregate Safety Specialist)
Pharmacovigilance Aggregate Reporting PBRER Review
EXECUTIVE SUMMARY & OPERATIONAL TAKEAWAYSARZON DOSSIER
  • Aggregate reporting evaluates cumulative safety profiles across hundreds of thousands of patient-years rather than single ICSR cases.
  • PBRER (ICH E2C R2) mandates holistic benefit-risk evaluation, replacing legacy PSUR formats for post-authorization drug monitoring.
  • Development Safety Update Reports (DSURs) are required annually for investigational drugs active in clinical trial phases.
  • Aggregate Safety Specialists command premium salary packages starting at ₹5.5 LPA for entry roles up to ₹16 LPA for senior authors.

1. What is Aggregate Safety Reporting?

While single case Individual Case Safety Reports (ICSRs) handle immediate 15-day expedited adverse event triage, Aggregate Safety Reporting involves periodic, cumulative analysis of all safety data accumulated for a medicinal product. Regulators use aggregate reports to determine whether a drug's overall benefit-risk balance remains favorable.
Regulatory Mandate

Under EMA GVP Module VII and FDA 21 CFR 314.80, periodic safety reports must be submitted on exact Data Lock Point (DLP) anniversaries.

2. PBRER vs PSUR: Key Structural Differences

The Periodic Benefit-Risk Evaluation Report (PBRER) introduced under ICH E2C(R2) shifted focus from simple risk listing to proactive benefit-risk assessment. Key sections include: - **Section 16**: Overall Signal Evaluation. - **Section 17**: Benefit Evaluation. - **Section 18**: Integrated Benefit-Risk Analysis for Approved Indications.

3. The DSUR Lifecycle in Clinical Trials

Development Safety Update Reports (DSURs) focus on active clinical trials (Phase I-IV), compiling safety data across all ongoing trials for an investigational drug.

4. Skills & Career Roadmap for Aggregate Writers

Pharmacy and medical graduates with 1-2 years of ICSR experience transition into Aggregate Writing, earning higher salary bands across top CROs and pharma MNCs.
VERIFIED COHORT PROGRAMME

Master Pharmacovigilance & Drug Safety Cohort at Arzon Global

Build audit-ready proof-of-work in software tools (Oracle Argus, ICD-10-CM, Medidata Rave, eCTD, SAS) with 12 weeks of structured cohort training and cryptographic certificate verification.

Related Healthcare Career Intelligence

Pharmacovigilance

The 2026 Pharmacovigilance Career Guide: Argus Safety, MedDRA & Fresher Salaries

An authoritative operational breakdown for Pharmacy, Medical, and Life Science graduates breaking into Drug Safety and Pharmacovigilance at Tier-1 GCCs and CROs.

READ DOSSIER →
Medical Coding

How to Break into Medical Coding in 2026: CPC Certification, ICD-10-CM & Salary Trends

Everything Life Science & Medical graduates need to know about AAPC CPC certification, ICD-10-CM/CPT coding guidelines, and securing medical coder jobs.

READ DOSSIER →
Clinical Data Management

Clinical Data Management (CDM) Careers 2026: Medidata Rave, Veeva & CDISC SDTM

Discover how Clinical Data Managers build electronic case report forms (eCRFs), manage query resolutions, and structure clinical trial data for global regulatory approval.

READ DOSSIER →
WhatsApp counsellor